Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi Fu

Showing results (1111-1120 of 1,122) with videos related to

Pageof 113
Sort By:
Nature Communications|March 31, 2026
Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trialLi-Ting Liu, Xue-Song Sun, Ting-Ting Quan, et al.
Annals of Surgical Oncology|August 26, 2025
Demographic and Clinicopathologic Characteristics of 3723 Patients with Primary Oral Squamous Cell Carcinoma: A Consecutive, Single-Center Study Over 11 Years (2012-2023)Yao Xiao, Lei-Ming Cao, Zhao-Qi Zhu, et al.
JAMA Oncology|June 18, 2025
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical TrialShan-Shan Guo, Xiao-Yun Li, Li-Ting Liu, et al.
The Lancet. Oncology|November 10, 2024
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trialSai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, et al.
Cell Reports. Medicine|June 13, 2020
Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal InstabilityJason E McDermott, Osama A Arshad, Vladislav A Petyuk, et al.
The Journal of Clinical Investigation|November 1, 2021
NK cell receptor and ligand composition influences the clearance of SARS-CoV-2Wan-Chen Hsieh, En-Yu Lai, Yu-Ting Liu, et al.
Cell Reports. Medicine|September 21, 2020
Correction: Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal InstabilityJason E McDermott, Osama A Arshad, Vladislav A Petyuk, et al.
Eclinicalmedicine|November 17, 2025
Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trialYu-Chen Li, Xiao-Yun Li, Kai-Qi Lan, et al.
Nature Communications|July 2, 2025
Single-cell signaling network profiling during redox stress reveals dynamic redox regulation in immune cellsYi-Chuan Wang, Ping-Hsun Wu, Wen-Chieh Ting, et al.
Cancer Communications (London, England)|February 25, 2022
XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX)Xiao-Dong Zhu, Ming-Zhu Huang, Yu-Sheng Wang, et al.
Pageof 113

Showing results (1111-1120 of 1,122) with videos related to

Sort By:
Pageof 113
Nature Communications|March 31, 2026
Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trialLi-Ting Liu, Xue-Song Sun, Ting-Ting Quan, et al.
Annals of Surgical Oncology|August 26, 2025
Demographic and Clinicopathologic Characteristics of 3723 Patients with Primary Oral Squamous Cell Carcinoma: A Consecutive, Single-Center Study Over 11 Years (2012-2023)Yao Xiao, Lei-Ming Cao, Zhao-Qi Zhu, et al.
JAMA Oncology|June 18, 2025
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical TrialShan-Shan Guo, Xiao-Yun Li, Li-Ting Liu, et al.
The Lancet. Oncology|November 10, 2024
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trialSai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, et al.
Cell Reports. Medicine|June 13, 2020
Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal InstabilityJason E McDermott, Osama A Arshad, Vladislav A Petyuk, et al.
The Journal of Clinical Investigation|November 1, 2021
NK cell receptor and ligand composition influences the clearance of SARS-CoV-2Wan-Chen Hsieh, En-Yu Lai, Yu-Ting Liu, et al.
Cell Reports. Medicine|September 21, 2020
Correction: Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal InstabilityJason E McDermott, Osama A Arshad, Vladislav A Petyuk, et al.
Eclinicalmedicine|November 17, 2025
Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trialYu-Chen Li, Xiao-Yun Li, Kai-Qi Lan, et al.
Nature Communications|July 2, 2025
Single-cell signaling network profiling during redox stress reveals dynamic redox regulation in immune cellsYi-Chuan Wang, Ping-Hsun Wu, Wen-Chieh Ting, et al.
Cancer Communications (London, England)|February 25, 2022
XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX)Xiao-Dong Zhu, Ming-Zhu Huang, Yu-Sheng Wang, et al.
Pageof 113